IMUX Stock Analysis: Buy, Sell, or Hold?
IMUX - Immunic, Inc. Common Stock
$14.80
-0.01 (-0.07%)
▼
5d:
-1.79%
30d:
+1.09%
90d:
+1186.96%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When IMUX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMUX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMUX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMUX is currently trading at $14.80, which is considered slightly high relative to its 30-day fair value range of $13.18 to $15.24.
Technical Outlook: Technically, IMUX is in a strong uptrend. Immediate support is located at $11.70, while resistance sits at $15.77.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.67 (+201.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMUX is in a strong uptrend. Immediate support is located at $11.70, while resistance sits at $15.77.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.67 (+201.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$13.18 -
$15.24
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 201.8% below Wall St target ($44.67)
Trading Range Analysis
30-Day Trading Range
$13.18 -
$15.24
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$2.53
(17.1%)
Support & Resistance Levels
Support Level
$11.70
Resistance Level
$15.77
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.17
Wall Street Target
$44.67
(+201.8%)
Share & Embed Analysis
Last updated: July 05, 2026 12:56 AM ET
Data refreshes hourly during market hours. Next update: 1:56 AM
Data refreshes hourly during market hours. Next update: 1:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMUX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$89 | 64 BUY |
